More On TPC Takeover
The management of C4 chemical supplier TPC Group is mounting a defense of its agreement to sell itself to the private equity (PE) firms SK Capital and First Reserve for $850 million.
The management of C4 chemical supplier TPC Group is mounting a defense of its agreement to sell itself to the private equity (PE) firms SK Capital and First Reserve for $850 million. Critics say the $40.00-per-share offer lowballs the company’s true value and potential.
Leading the charge against the deal has been Sandell Asset Management, which owns a 7% stake in TPC. In a white paper, Sandell says TPC could be worth as much as $71.00 per share. The firm calls the $40.00 offer “a sweetheart deal for the PE buyers and management, allowing them to steal the company on the cheap from shareholders without a full and proper auction.”
In its proxy statement, issued last week to detail deal information to shareholders, TPC describes the months before the agreement. After SK and First Reserve first approached TPC in December 2011, nine other parties expressed interest in acquiring TPC. Six of these were “strategic bidders,” most likely other chemical companies. However, few of these interactions yielded solid acquisition proposals, and by the end of July TPC was negotiating with SK and First Reserve exclusively.
TPC also defends the planned sale by pointing to expensive and risky growth initiatives, which would be challenging for the firm to fund by itself. Last week, for example, the firm’s board approved a $265 million project to restart a dehydrogenation unit that would convert isobutane into isobutylene. TPC also wants to build a plant that would make butadiene from n-butane.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance